Pharma Journalist -

AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma…
Read More...

Astellas Pharma Inc. and Taysha Gene Therapies, Inc. announced a strategic investment to support the advancement of Taysha's adeno-associated virus (AAV) gene therapy development…
Read More...

SAE Media Group reports: The 14th Annual RNA Therapeutics Conference is set to return in February 2023 with a key focus on mRNA therapeutic applications. SAE Media Group is delighted…
Read More...

Daiichi Sankyo received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) of quizartinib in combination with standard…
Read More...

Kite, a Gilead Company and Refuge Biotechnologies, Inc. announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for…
Read More...

ARS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review ARS’ New Drug Application (NDA) for neffy for the emergency treatment…
Read More...

Sumitovant Biopharma Ltd. in conjunction with parent company Sumitomo Pharma Co., Ltd. and Myovant Sciences announced today that they have entered into a definitive agreement pursuant…
Read More...

AbbVie announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active…
Read More...

HOOKIPA Pharma Inc. a company developing a new class of immunotherapies based on its proprietary arenavirus platform, announced a strategic collaboration and license agreement with…
Read More...

Corium, LLC a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Gurnet Point Capital (“Gurnet Point”), a…
Read More...